Cargando…
Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C
Mucosal immunity plays an important role in the control of viral respiratory infections like SARS-CoV-2. While systemic immune responses against the SARS-2-CoV-2 have been studied in children, there is no information on mucosal antibody response, especially in the lower respiratory tract of children...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879098/ https://www.ncbi.nlm.nih.gov/pubmed/35214728 http://dx.doi.org/10.3390/vaccines10020270 |
_version_ | 1784658817511849984 |
---|---|
author | Tang, Juanjie Randolph, Adrienne G. Novak, Tanya Walker, Tracie C. Loftis, Laura L. Zinter, Matt S. Irby, Katherine Khurana, Surender |
author_facet | Tang, Juanjie Randolph, Adrienne G. Novak, Tanya Walker, Tracie C. Loftis, Laura L. Zinter, Matt S. Irby, Katherine Khurana, Surender |
author_sort | Tang, Juanjie |
collection | PubMed |
description | Mucosal immunity plays an important role in the control of viral respiratory infections like SARS-CoV-2. While systemic immune responses against the SARS-2-CoV-2 have been studied in children, there is no information on mucosal antibody response, especially in the lower respiratory tract of children coronavirus disease 2019 (COVID-19) and post-infectious multisystem inflammatory syndrome in children (MIS-C) against emerging SARS-CoV-2 variants. Therefore, we evaluated neutralizing antibody responses in paired plasma and endotracheal aspirates of pediatric severe, acute COVID-19 or MIS-C patients against SARS-CoV-2 WA1/2020, as well as against variants of concern (VOCs). Neutralizing antibody responses against the SARS-CoV-2 WA1/2020 strain in pediatric plasma were 2-fold or 35-fold higher compared with the matched endotracheal aspirate in COVID-19 or MIS-C patients, respectively. In contrast to plasma, neutralizing antibody responses against the VOCs and variants of interest (VOIs) in endotracheal aspirates were lower, with only one endotracheal aspirate demonstrating neutralizing titers against the Iota, Kappa, Beta, Gamma, and Omicron variants. In conclusion, our findings suggest that children and adolescents with severe COVID-19 or MIS-C have weak mucosal neutralizing antibodies in the trachea against circulating SARS-CoV-2 Omicron and other VOCs, which may have implications for recovery and for re-infection with emerging SARS-CoV-2 variants. |
format | Online Article Text |
id | pubmed-8879098 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88790982022-02-26 Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C Tang, Juanjie Randolph, Adrienne G. Novak, Tanya Walker, Tracie C. Loftis, Laura L. Zinter, Matt S. Irby, Katherine Khurana, Surender Vaccines (Basel) Article Mucosal immunity plays an important role in the control of viral respiratory infections like SARS-CoV-2. While systemic immune responses against the SARS-2-CoV-2 have been studied in children, there is no information on mucosal antibody response, especially in the lower respiratory tract of children coronavirus disease 2019 (COVID-19) and post-infectious multisystem inflammatory syndrome in children (MIS-C) against emerging SARS-CoV-2 variants. Therefore, we evaluated neutralizing antibody responses in paired plasma and endotracheal aspirates of pediatric severe, acute COVID-19 or MIS-C patients against SARS-CoV-2 WA1/2020, as well as against variants of concern (VOCs). Neutralizing antibody responses against the SARS-CoV-2 WA1/2020 strain in pediatric plasma were 2-fold or 35-fold higher compared with the matched endotracheal aspirate in COVID-19 or MIS-C patients, respectively. In contrast to plasma, neutralizing antibody responses against the VOCs and variants of interest (VOIs) in endotracheal aspirates were lower, with only one endotracheal aspirate demonstrating neutralizing titers against the Iota, Kappa, Beta, Gamma, and Omicron variants. In conclusion, our findings suggest that children and adolescents with severe COVID-19 or MIS-C have weak mucosal neutralizing antibodies in the trachea against circulating SARS-CoV-2 Omicron and other VOCs, which may have implications for recovery and for re-infection with emerging SARS-CoV-2 variants. MDPI 2022-02-10 /pmc/articles/PMC8879098/ /pubmed/35214728 http://dx.doi.org/10.3390/vaccines10020270 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tang, Juanjie Randolph, Adrienne G. Novak, Tanya Walker, Tracie C. Loftis, Laura L. Zinter, Matt S. Irby, Katherine Khurana, Surender Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C |
title | Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C |
title_full | Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C |
title_fullStr | Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C |
title_full_unstemmed | Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C |
title_short | Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C |
title_sort | systemic and lower respiratory tract immunity to sars-cov-2 omicron and variants in pediatric severe covid-19 and mis-c |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879098/ https://www.ncbi.nlm.nih.gov/pubmed/35214728 http://dx.doi.org/10.3390/vaccines10020270 |
work_keys_str_mv | AT tangjuanjie systemicandlowerrespiratorytractimmunitytosarscov2omicronandvariantsinpediatricseverecovid19andmisc AT randolphadrienneg systemicandlowerrespiratorytractimmunitytosarscov2omicronandvariantsinpediatricseverecovid19andmisc AT novaktanya systemicandlowerrespiratorytractimmunitytosarscov2omicronandvariantsinpediatricseverecovid19andmisc AT walkertraciec systemicandlowerrespiratorytractimmunitytosarscov2omicronandvariantsinpediatricseverecovid19andmisc AT loftislaural systemicandlowerrespiratorytractimmunitytosarscov2omicronandvariantsinpediatricseverecovid19andmisc AT zintermatts systemicandlowerrespiratorytractimmunitytosarscov2omicronandvariantsinpediatricseverecovid19andmisc AT irbykatherine systemicandlowerrespiratorytractimmunitytosarscov2omicronandvariantsinpediatricseverecovid19andmisc AT khuranasurender systemicandlowerrespiratorytractimmunitytosarscov2omicronandvariantsinpediatricseverecovid19andmisc |